- Home
- WERN vs IRON Comparison
WERN vs IRON Comparison
Compare WERN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- IRON
- Stock Information
- Founded
- WERN 1956
- IRON 2017
- Country
- WERN United States
- IRON United States
- Employees
- WERN N/A
- IRON N/A
- Industry
- WERN Trucking Freight/Courier Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- IRON Health Care
- Exchange
- WERN Nasdaq
- IRON Nasdaq
- Market Cap
- WERN 2.3B
- IRON 1.9B
- IPO Year
- WERN N/A
- IRON N/A
- Fundamental
- Price
- WERN $37.16
- IRON $60.52
- Analyst Decision
- WERN Hold
- IRON Strong Buy
- Analyst Count
- WERN 15
- IRON 10
- Target Price
- WERN $37.33
- IRON $73.70
- AVG Volume (30 Days)
- WERN 655.8K
- IRON 263.4K
- Earning Date
- WERN 02-06-2025
- IRON 03-20-2025
- Dividend Yield
- WERN 1.51%
- IRON N/A
- EPS Growth
- WERN N/A
- IRON N/A
- EPS
- WERN 0.73
- IRON N/A
- Revenue
- WERN $3,097,524,000.00
- IRON N/A
- Revenue This Year
- WERN N/A
- IRON N/A
- Revenue Next Year
- WERN $4.03
- IRON N/A
- P/E Ratio
- WERN $50.66
- IRON N/A
- Revenue Growth
- WERN N/A
- IRON N/A
- 52 Week Low
- WERN $33.12
- IRON $25.60
- 52 Week High
- WERN $42.48
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- WERN 52.02
- IRON 47.35
- Support Level
- WERN $36.19
- IRON $58.15
- Resistance Level
- WERN $37.51
- IRON $61.08
- Average True Range (ATR)
- WERN 0.83
- IRON 2.96
- MACD
- WERN 0.27
- IRON -0.41
- Stochastic Oscillator
- WERN 89.30
- IRON 43.25
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - TTS and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.